Disease Modifying Antirheumatic Drugs Use in Patients With Rheumatoid Arthritis: Experience From a Peruvian Referral Center

Luza, Solis; a, Elena Mar; Segami, M I; Poma, Alberto G.; Alva, Magaly; Eda, Izumi; Chung, C-K.

doi:10.1097/01.rhu.0000226605.76826.5a

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite RA affecting approximately 1% of the world's population, 1–3 our understanding of the underlying pathophysiology remains incomplete and the optimal strategy for controlling disease in patients with RA in many cases remains unclear 4 . Although the benefits of early treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs) and disease‐modifying antirheumatic drugs (DMARDs) are indisputable, 5–11 long‐term systemic therapy fails in a number of cases and the use of these agents can be limited by gastrointestinal side‐effects. Biological agents, such as anti‐tumour necrosis factor (TNF) antibody, have shown marked improvement in outcomes in RA patients; 12–15 however, the use of such treatments may carry an increased risk of other diseases, such as tuberculosis, systemic lupus erythematosus and malignancy 16 .…”

Section: Introductionmentioning

confidence: 99%

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

Wang¹,

Gu²,

Xu³

et al. 2007

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. The present study investigated the therapeutic effects of both single and combination treatment with Yunke (technetium-99 conjugated with methylene diphosphonate; (99)Tc-MDP) and colloidal chromic phosphate (32)P (phosphonium-32) in rats with adjuvant arthritis (AA). 2. Rats were randomly allocated to one of five groups: (i) normal control group (sham operated and treated with normal saline); (ii) AA control group (arthritis induced with adjuvant and treated with normal saline); (iii) (32)P colloid group (arthritis induced with adjuvant and treated with a single intra-articular injection of colloidal chromic phosphate phosphonium-32 (0.02 mCi) and i.p. injections of normal saline every other day); (iv) Yunke group (arthritis induced with adjuvant and treated with i.p. Yunke (2.5 x 10(-3) microg/kg) every other day and single intra-articular injection of normal saline); and (v) combination group (arthritis induced with adjuvant and treated with a combination of both therapies). 3. The left-to-right diameter (LRD) of the left hind ankle, serum levels of tumour necrosis factor (TNF) and interleukin (IL)-1b and histological sections of the ankle joints were examined at different time points. 4. The LRD of the left hind ankle was smaller for the combination group compared with (32)P colloid alone at Week 4 (7.11 +/- 0.28 vs 7.57 +/- 0.24 mm, respectively; P < 0.001). The combination treatment was more effective than (32)P colloid alone in decreasing serum TNF (1.614 +/- 0.368 vs 1.977 +/- 0.255 ng/mL, respectively; P = 0.002 for Week 4) and IL-1b (0.271 +/- 0.027 vs 0.308 +/- 0.020 ng/mL, respectively for Week 4; 0.209 +/- 0.023 vs 0.255 +/- 0.016 ng/mL, respectively for Week 6; both P = 0.001). Histologically, the combination group exhibited less synovium proliferation compared with Yunke treatment alone and decreased inflammatory cell infiltration compared with (32)P colloid alone. 5. In conclusion, the combination of Yunke and (32)P colloid is more effective in the treatment of AA in rats compared with Yunke or (32)P colloid alone.

show abstract

Section: Introductionmentioning

confidence: 99%

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

Wang¹,

Gu²,

Xu³

et al. 2007

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

Disease Modifying Antirheumatic Drugs Use in Patients With Rheumatoid Arthritis: Experience From a Peruvian Referral Center

Cited by 1 publication

References 0 publications

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

Contact Info

Product

Resources

About

Disease Modifying Antirheumatic Drugs Use in Patients With Rheumatoid Arthritis: Experience From a Peruvian Referral Center

Cited by 1 publication

References 0 publications

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; 99Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; 99Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

Contact Info

Product

Resources

About

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; ⁹⁹Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS